Unlocking Heart Safety: Journey into Cardiotoxicity Testing
Dive into the Heartbeat of Drug Safety with Our Advanced Cardiotoxicity Tests
Embark on a revolutionary exploration of drug safety as we unveil the power of hiPSC-CMs, 3D cardiospheres, and 3D mini hearts. At Bonds Bio, we believe in fortifying drug development right from its inception by prioritizing robust cardiotoxicity testing through cardiac organoids.
Why Cardiotoxicity Matters:
Cardiotoxicity, the potential harm to the heart caused by drugs, is a critical concern in drug development. Identifying these risks early is paramount for creating safer medications, saving time, money, and, most importantly, lives.
Our Cutting-Edge Approach:
Harnessing the precision of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), along with the dynamic insight from 3D cardiospheres and 3D mini hearts (cardiac organoids), we've engineered a platform that scrutinizes cardiotoxicity at its core.
The Importance of Early Testing:
Testing for cardiotoxicity in the early stages of drug discovery is not just a step; it's a leap towards safer pharmaceuticals and less heart issues. Our advanced platform ensures that potential risks to the heart are unveiled at the earliest stages, empowering you to refine drug candidates with greater confidence.
Unveiling Unprecedented Complexity: 2D hiPSC-CMs in Cardiotoxicity
Despite exhibiting fetal heart-like traits, including a significant expression of mature cardiomyocyte proteins like Myosin light chain 2v (ventricular) only after 60-120 days in culture, hiPSC-CMs attain a level of complexity unparalleled in genetically modified cells or animal-based models.
Elevating Maturation: The Power of 3D Cardiospheres in Cardiotoxicity
Experience the profound impact of introducing tridimensional conditions in hiPSC-CMs cultivation. Observe the enhancement in maturation at an earlier stage. The intricate physical and chemical crosstalk within cardiomyocytes forming the cardiosphere not only accelerates maturation but also trims a month off cultivation time, making it a potent alternative for exploring new compound cardiotoxicity.
Cardiospheres Outperform 2D hiPSC-Cardiomyocytes in DOFETILIDE Response
Experience a paradigm shift in cardiotoxicity evaluation as our data unveils the superior mimicry of toxicity-response to DOFETILIDE (hERG-blocker) by cardiospheres compared to traditional 2D hiPSC-Cardiomyocytes. Discover the future of accurate and predictive cardiotoxicity assessments with Bonds Bio.
Introducing the Future: Mini Hearts (Cardiac Organoids)
Prepare for a groundbreaking leap in cardiovascular research with our next-generation cardio models – the Cardiac Organoids, or mini hearts. These self-assembled wonders replicate key steps of cardiac embryogenesis, providing a revolutionary approach to studying heart development and function.
Key Features:
- Self-Assembly: Witness the fascinating process of self-assembly, mirroring critical stages of cardiac embryogenesis.
- Cell Diversity: Explore the richness of different cell types intricately woven into the fabric of our Cardiac Organoids.
- Chamber Formation: Marvel at the extraordinary capacity of these mini hearts to form chambers, akin to the complexity found in an adult heart.
These Cardiac Organoids redefine the possibilities in cardiovascular modeling, offering an unparalleled glimpse into the intricacies of heart development.
Copyright © 2024 Bonds Biosystems Corporation - All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.